Skip to main content

Table 3 Cumulative effect of favorable and unfavorable genotypes on ovarian cancer risk

From: Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy

Analysis Polymorphisms Number of variants Controls n (%) Cases n (%) OR (±95%CI) P
Favorable effect p.Arg952Lys ATP7B 0 52 (15.7) 46 (23.78) 1 (ref)  
p.Arg72Pro TP53 1 162 (48.8) 96 (49.5) 0.67 (0.42-1.07) 0.095
  2 118 (35.5) 52 (26.8) 0.50 (0.30-0.83) 0.008
Unfavorable effect p.Ile1145 = ABCB1 0 27 (8.1) 3 (1.06) 1 (ref)  
p.Asp1853Asn ATM 1 95 (28.6) 42 (22.3) 3.98 (1.13-13.97) 0.030
p.Ser406Ala ATP7B 2 163 (49.1) 104 (55.3) 5.74 (1.69-19.50) 0.005
3 47 (14.2) 39 (20.8) 7.47 (2.08-26.85) 0.002
  1. Statistically significant analyses are in bold.